Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook for its stock performance in the near term [6]. Core Insights - The company is expanding its presence in the medical aesthetics sector, with a focus on integrating cosmetic and medical products. Recent approvals for differentiated injection products highlight the company's strategic foresight in selecting investment targets [2][6]. - The main brand, Winona, has shown improvement in its performance, particularly during the 2025 Double Eleven shopping festival, where it ranked 8th in the beauty category on Tmall, reflecting a slight increase from the previous year [2]. - The company has made significant investments in various medical aesthetic ventures, including a recent investment in Yizheng Biotechnology and ongoing collaborations with Weimai Medical to explore innovative perioperative skin care solutions [2]. Financial Summary - The company’s market capitalization is approximately 19.87 billion yuan, with a circulating market value of the same amount. The stock has seen a 52-week high of 50.85 yuan and a low of 39.34 yuan, with a price-to-earnings (P/E) ratio ranging from 32.78 to 42.38 [5]. - Profit forecasts indicate a net profit attributable to the parent company of 5.3 billion yuan in 2025, with expected growth rates of 6.3%, 24.7%, and 15.5% for the years 2025, 2026, and 2027 respectively [6][7].

【事项】 公 司 研 究 / 美 容 护 理 / 证 券 研 究 报 告 贝泰妮（300957）动态点评 主品牌表现逐步改善，持续延伸医美领 域布局，关注经营向好趋势 2026 年 02 月 25 日 成都伊臻生物科技有限公司旗下"注射用聚左旋乳酸填充剂"，于 26 年 1 月获批 III 类医疗器械注册证，为全球首个明确获批用于颞部填充 适应症的聚左旋乳酸产品，亦为我国在该部位的首次批准，贝泰妮持 有成都伊臻生物母公司伊正（苏州）生物科技 15.73%股权，为其重要 战略投资者、单体最大股东。 【评论】 公司于医美领域布局不断丰富，有助于深化"妆械联合"逻辑。公司 于 2023 年投资伊正生物，当前差异化的注射剂产品获批亦体现了公 司前瞻布局筛选标的的能力，除医美注射剂外，公司在医美光电赛道 同样有较多布局，如：2023、2024 年，两度投资威脉医疗，旗下核心 射频抗衰产品 YOUMAGIC 舒立缇已经于 2024 年获批，贝泰妮已经 开始联合威脉开始探索围术期皮肤护理的创新性解决办法；2025 年投 资专注于高端医美光电设备研发的苏州紫菘医疗科技。公司在医美注 射剂、光电设备的投资布局不断完善，未来亦可 ...

Core Insights - The beauty industry is undergoing a technological transformation, with the integration of medical research driving value upgrades in cosmetics. This dual integration of medicine and beauty is defining a new competitive logic in the industry [3][6][24]. Industry Trends - The 20th China Dermatology Association (CDA) conference showcased over 10,000 dermatologists and more than 100 companies, including both domestic and international beauty brands, highlighting the industry's focus on scientific collaboration [3][4]. - The concept of "medical-research co-creation" emerged as a key theme, with brands actively participating in discussions on how to contribute to the skin science system, moving from mere users of research to active participants in scientific understanding and industry standards [7][24]. Brand Innovations - Winona, a brand known for its scientific foundation, showcased its "NUTE" principle at CDA 2025, which emphasizes clinical needs, unique mechanisms, technology empowerment, and credible evidence in product development [10]. - HBN, a domestic skincare brand, initiated the establishment of a group standard for "Cosmetic Efficacy Evidence Weight Assessment Guidelines," aiming to shift the industry from experience-driven to evidence-based competition [11][13]. - Estee Lauder's Clinique presented a white paper on the causes and distribution patterns of post-inflammatory hyperpigmentation, demonstrating the brand's commitment to scientific validation [14][16]. Research and Development - The integration of research and clinical application is evident in the initiatives taken by brands like Giant Bio and Zhenyan Bio, which are expanding the boundaries of medical-research co-creation through innovative collagen products and clinical studies [20][22]. - The collaboration between brands and medical experts is evolving, with companies like Ximu Yuan conducting extensive research on sensitive skin, showcasing a shift from being mere users of research to contributors to scientific inquiry [24][25]. Future Outlook - The CDA conference highlighted a significant shift in the beauty industry towards a more scientific and collaborative approach, with brands, medical institutions, and research organizations forming a new ecosystem that emphasizes shared data and mutual advancement [47][48]. - The focus on original ingredient research is becoming a core strategy for leading domestic brands, as they aim to differentiate themselves from homogenized competition [38][39].

Core Viewpoint - The skincare industry is shifting from a focus on "ingredients" to a deeper understanding of "full-chain value," exemplified by Clinique's UP302 approval for new whitening efficacy, marking a significant milestone in the efficacy skincare market [2][3][9]. Industry Trends - The efficacy skincare market in China is at a critical turning point in 2025, moving away from ingredient-driven marketing to a trust-based model where scientific validation is paramount [6][7]. - The implementation of the 2021 Cosmetics Supervision and Administration Regulation has ushered in a new era of scientific regulation, requiring efficacy claims to be backed by clinical or experimental data [7][9]. Clinique's Innovation - Clinique's UP302 (Dimethoxyphenyl Propyl Hydroxyphenol) is the first ingredient to receive regulatory approval for expanded whitening efficacy since the new regulations took effect, showcasing the brand's commitment to scientific innovation and regulatory compliance [3][9]. - The development of UP302 involved over 2,200 plant screenings, leading to a stable and effective formulation that enhances skin penetration and maintains high activity at low concentrations [15][17]. Mechanisms of Action - UP302 operates through a "three-dimensional regulatory system," targeting: 1. Source suppression of melanin through selective inhibition of tyrosinase activity [20]. 2. Glycation intervention to reverse "glycation-induced darkening" [20]. 3. Inflammation regulation to prevent post-inflammatory hyperpigmentation (PIH) [21]. Clinical Integration - Clinique's "makeup-device combination" strategy integrates daily skincare with medical-grade products, providing a comprehensive management approach for patients undergoing aesthetic procedures [22][24]. - The brand has published the "2025 Aesthetic White Paper," which outlines a systematic care path centered around UP302, offering a replicable solution for medical institutions [28][30]. Future Outlook - The approval of UP302 and the establishment of a credible efficacy verification system signify a shift in the skincare market towards evidence-based competition, where scientific credibility will be the key differentiator [32][33]. - Clinique's approach emphasizes the importance of building a trust-based relationship with consumers through transparent scientific communication and evidence [32][33].

Core Viewpoint - The article highlights the significant issue of post-treatment hyperpigmentation (referred to as "返黑") in the Chinese medical aesthetics market, with a reported 28% recurrence rate after light therapy treatments, which undermines the initial goals of skin whitening and brightening [3][5][6]. Group 1: Market Insights - The compound annual growth rate (CAGR) for post-treatment care products in China's medical aesthetics sector is projected to reach 30% from 2022 to 2026, with the market size expected to hit 25.38 billion yuan by 2026 [3]. - A survey by Estée Lauder in 2024 indicates that 84% of consumers participate in light therapy projects, making it the dominant choice in the market [3]. - The white paper reveals that 95% of consumers pursue light therapy primarily for skin whitening, yet over 25% experience worsening pigmentation [5][6]. Group 2: Consumer Challenges - The article discusses the psychological impact of post-treatment hyperpigmentation, with 90% of affected individuals feeling distressed, and 24% experiencing extreme distress [11][12]. - The unique skin characteristics of Chinese consumers, such as more active melanocytes and weaker skin barriers, contribute to a higher incidence of post-inflammatory hyperpigmentation (PIH) [7][9]. - Many consumers lack consistent sun protection awareness, particularly during autumn and winter, which exacerbates the issue of post-treatment pigmentation [9]. Group 3: Solutions and Innovations - Clinique has introduced a systematic solution called "妆械联合" (makeup and medical device integration) to address the complexities of post-treatment skin care, combining medical-grade products with daily skincare routines [14][16]. - The CX series, a new line of medical device products, includes a collagen-based wound care solution that enhances healing and skin barrier repair [17]. - The upgraded 302 Photon Laser Bottle aims to prevent post-treatment pigmentation and enhance daily whitening, utilizing a targeted formula that has shown promising clinical results [19][20]. Group 4: Industry Evolution - The article emphasizes the need for a paradigm shift in the medical aesthetics industry from short-term treatments to long-term management strategies, as highlighted by Clinique's approach [24][26]. - Clinique's integration of medical device technology with skincare formulations represents a significant advancement in addressing the specific needs of Asian skin types [26]. - The white paper serves as a scientific guide for consumers, aiming to establish industry standards and provide a comprehensive solution for pre-, intra-, and post-treatment care [22][24].

Core Insights - Waldencast, the parent company of Obagi Medical, has announced the acquisition of Novaestiq, a company specializing in beauty and medical skin innovations, which includes exclusive rights to sell Saypha® hyaluronic acid injection gel products in the U.S. market [1][2] - This acquisition marks Obagi's entry into the "medical device" sector, which is gaining traction as over 22 beauty brands have launched more than 40 "medical device" products [1][13] Company Overview - Waldencast was founded by former L'Oréal executives and aims to build a leading global beauty and health platform through the development and acquisition of high-growth brands, including Obagi and Milk Makeup [2] - The acquisition of Novaestiq is a strategic move to expand Obagi's product line in the U.S. dermal filler market [2] Market Potential - The U.S. dermal filler market is projected to reach $2.2 billion by 2029, indicating significant growth potential for Waldencast's investment [3] - Saypha® has sold over 110 million units in more than 80 countries but is still awaiting FDA approval for the U.S. market [3] Financial Performance - Waldencast reported a net revenue of $274 million for 2024, a 25.5% year-over-year increase, with Obagi contributing $149 million, reflecting a 26.9% growth [7] - In Q1 2025, Waldencast's net revenue was $65.4 million, a 4.1% decline, while Obagi's revenue grew by 7.1% to $36.2 million [8] Competitive Landscape - The U.S. is the largest market for injectable medical aesthetics, accounting for approximately 20.8% of global treatment procedures [9] - The market for hyaluronic acid injectables is growing steadily, making it a competitive space with established brands like Restylane already present [9] Strategic Direction - Waldencast aims to leverage Obagi's existing market influence to capture new growth opportunities in the medical aesthetics sector [3][7] - The company is focusing on scientific innovation and clinical data-backed products to enhance its market position [7] Industry Trends - The global medical aesthetics market is expected to reach $35.3 billion by 2030, with a compound annual growth rate of 12.8% from 2024 to 2030 [13] - The trend of "cosmetic-medical integration" is becoming more prevalent, with beauty brands increasingly developing and marketing medical device products [13]

Core Insights - The skincare market for international brands like Estée Lauder and L'Oréal is facing challenges, prompting a shift towards the medical aesthetics sector [1][4] - Estée Lauder has partnered with Jiahui Medical to establish a clinical research center focused on post-surgical skincare solutions [1][5] - The beauty industry is witnessing a trend towards "medical beauty," with brands integrating effective skincare products with medical aesthetics [4][6] Group 1: Company Strategies - Estée Lauder's brands, including La Mer and Clinique, are launching medical device products aimed at post-surgical recovery, indicating a strategic pivot towards medical aesthetics [1][5] - L'Oréal has been proactive in the medical aesthetics space, introducing products like the "Platinum Research" collagen injection and investing in high-end medical chains [6][7] - Amorepacific has also entered the market with its high-end brand "AP," focusing on post-surgical skincare products priced between 2000-3000 RMB [5][6] Group 2: Market Dynamics - The high-end skincare market is experiencing a significant decline, with Estée Lauder reporting an 8% drop in skincare sales in Q3 2024 and a further 12% in Q4 2024, leading to a total revenue loss of $300 million [4] - Competitors like Beiersdorf are also struggling, with its luxury brand La Prairie seeing a 15% sales decline in 2023 and a 6% drop in 2024 [4] - The domestic medical aesthetics market is becoming increasingly competitive, with companies like Aimeike facing growth slowdowns despite a 5.45% revenue increase in 2024 [9][10] Group 3: Future Outlook - Aimeike's acquisition of an 85% stake in Korean company REGEN for approximately 1.4 billion RMB highlights the need for companies to strengthen their technological capabilities in the face of rising competition [11] - The competition between international beauty brands and domestic medical aesthetics firms is intensifying, focusing on brand strength and clinical validation versus technological barriers and channel control [11]